Science

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese/LinkedIn

Feb 8, 2025, 07:34

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

Ciro Franzese, Associate Professor in Radiation Oncology at Humanitas University, shared on LinkedIn:

“Joining forces against kidney cancer!

Proud to have contributed to an international multicenter study of stereotactic radiotherapy for renal cell carcinoma.

SBRT is confirmed as a valid therapeutic option with:

96% local control at 5 years
Good preservation of renal function
acceptable toxicity profile, with only 1% of events grade ≥ 3

A step forward to offer inoperable patients an effective and non-invasive therapeutic option.”

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series

Authors: Ludwige Abancourt, et al.

Ciro Franzese: An international multicenter study of stereotactic radiotherapy for renal cell carcinoma

cancer Ciro Franzese fight against cancer Global awareness Global fight against cancer Large Multicenter Series non-invasive OncoDaily Oncology renal cell carcinoma Stereotactic Radiotherapy

100 Oncologists, One Community: Reflections from the First ESO College Convention

Gevorg Tamamyan: "Fertility News" is on the Way

JCO on a Jamaican Beach: The Journey of Joyson Karakunnel

Patrick Soon-Shiong: NK cells matter!

Anas Younes Has Been Appointed Chief Medical Officer at AstraZeneca